A study on the clinical value of <sup>18</sup>F‑fluorodeoxyglucose positron emission tomography/computed tomography combined with serum squamous cell carcinoma antigen in diagnosing recurrence/metastases in patients with early metaphase cervical cancer

Qi,Chi; He,Shasha; Cai,Liang; Zhang,Li; Ding,Haoyuan; Chen,Yue

doi:10.3892/ol.2021.13007

A study on the clinical value of ¹⁸F‑fluorodeoxyglucose positron emission tomography/computed tomography combined with serum squamous cell carcinoma antigen in diagnosing recurrence/metastases in patients with early metaphase cervical cancer

Authors:
- Chi Qi
- Shasha He
- Liang Cai
- Li Zhang
- Haoyuan Ding
- Yue Chen
View Affiliations

Affiliations: Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China, Department of Radiology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China
Published online on: August 24, 2021 https://doi.org/10.3892/ol.2021.13007
Article Number: 746
Copyright: © Qi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical cancer (CC) is the most common female genital tract malignancy, with repercussions on the psychophysiological health of female patients. Patients with CC are faced with a high risk of postoperative recurrence and metastases. The present study aimed to evaluate the clinical value of 18F‑fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) combined with serum squamous cell carcinoma antigen (SCC‑Ag) in the diagnosis of postoperative recurrence/metastases in patients with early stage CC. This was a prospective follow‑up study on 246 patients who received surgery for early stage CC. The results of clinical follow‑up and pathological examination were taken as the gold standard. The diagnostic sensitivity, specificity, positive predictive value, negative predictive value and area under the receiver operating characteristic (ROC) curve were calculated for PET/CT, serum SCC‑Ag determination and the combined PET/CT and serum SCC‑Ag method. Results demonstrated that 90.11% patients completed the follow‑up, and the median follow‑up time was 22 months (range, 7‑42 months). Tumor recurrence or metastasis was confirmed in a total of 137 patients (55.7%), including 18 deaths. The diagnostic sensitivity of PET/CT scan combined with serum SCC‑Ag determination for postoperative metastases/recurrence in patients with early stage CC was 93.43% (95% CI, 0.875‑0.967). The specificity was 92.67% (95% CI, 0.856‑0.965), the positive predictive value was 94.12% (95% CI, 0.884‑0.972), the negative predictive value was 91.81% (95% CI, 0.846‑0.959) and the area under the ROC curve was 0.930±0.019 (95% CI, 0.893‑0.968; P<0.001). The results also revealed that the serum SCC‑Ag level was positively correlated with SUVmax (r=0.458; P<0.001). The results from the present study demonstrated that for patients with early metaphase CC, PET/CT scan combined with serum SCC‑Ag determination during the follow‑up was capable of earlier, more comprehensive and more accurate detection of recurrence/metastatic lesions, which is of high clinical application value.

View Figures

View References

1	Cohen PA, Jhingran A, Oaknin A and Denny L: Cervical cancer. Lancet. 393:169–182. 2019. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I and Bray F: Global cancer observatory: Cancer today. International Agency for Research on Cancer; Lyon: 2018
3	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
4	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
5	Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
6	Martins EB, Chojniak R, Kowalski LP, Nicolau UR, Lima EN and Bitencourt AG: Diffusion-weighted MRI in the assessment of early treatment response in patients with squamous-cell carcinoma of the head and neck: Comparison with morphological and PET/CT Findings. PLoS One. 10:e01400092015. View Article : Google Scholar : PubMed/NCBI
7	Harashavardhan NS, Naveen Kumar S, Uday Kumar NS, Ezhilarasi R and Bhavani B: A prospective analysis of magentic resonance imaging and computed tomography in staging with uterine cervix carcinoma: A single centre experience. J Chalmeda Anand Rao Institute Med Sci. 16:158–162. 2018.
8	Lee SI, Catalano OA and Dehdashti F: Evaluation of gynecologic cancer with MR imaging, 18F-FDG PET/CT, and PET/MR imaging. J Nucl Med. 56:436–443. 2015. View Article : Google Scholar : PubMed/NCBI
9	Gee MS, Atri M, Bandos AI, Mannel RS, Gold MA and Lee SI: Identification of distant metastatic disease in uterine cervical and endometrial cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 multicenter trial. Radiology. 287:176–184. 2018. View Article : Google Scholar : PubMed/NCBI
10	Dolgun ZN, Altintas AS, Ivan C and Balkanli P: Comparison of preoperative magnetic resonance imaging results with postoperative pathologic results in early stage uterine cervical cancer. Eur J Gynaecol Oncol. 39:935–938. 2018.
11	Herrera FG and Prior JO: The role of PET/CT in cervical cancer. Front Oncol. 3:342013. View Article : Google Scholar : PubMed/NCBI
12	Ramlov A, Kroon PS, Jurgenliemk-Schulz IM, Leeuw AA, Gormsen LC, Fokdal LU, Tanderup K and Lindegaard JC: Impact of radiation dose and standardized uptake value of (18)FDG PET on nodal control in locally advanced cervical cancer. Acta Oncol. 54:1567–1573. 2015. View Article : Google Scholar : PubMed/NCBI PubMed/NCBI
13	Selman TJ, Mann C, Zamora J, Appleyard TL and Khan K: Diagnostic accuracy of tests for lymph node status in primary cervical cancer: A systematic review and meta-analysis. CMAJ. 178:855–862. 2008. View Article : Google Scholar : PubMed/NCBI
14	Salvatici M, Achilarre MT, Sandri MT, Boveri S, Vanna Z and Landoni F: Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: Role in the early diagnosis of recurrence. Gynecol Oncol. 142:115–119. 2016. View Article : Google Scholar : PubMed/NCBI
15	Shimura K, Mabuchi S, Yokoi T, Sasano T, Sawada K, Hamasaki T and Kimura T: Utility of serum squamous cell carcinoma antigen levels at the time of recurrent cervical cancer diagnosis in determining the optimal treatment choice. J Gynecol Oncol. 24:321–329. 2013. View Article : Google Scholar : PubMed/NCBI
16	Fu J, Wang W, Wang Y, Liu C and Wang P: The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer. Radiat Oncol. 14:1462019. View Article : Google Scholar : PubMed/NCBI
17	Choi KH, Lee SW, Yu M, Jeong S, Lee JW and Lee JH: Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: A multi-institutional analysis. J Gynecol Oncol. 30:e12019. View Article : Google Scholar : PubMed/NCBI
18	Huang EY, Huang YJ, Chanchien CC, Lin H, Wang CJ, Sun LM, Tseng CW, Tsai CC, Ou YC, Fu HC, et al: Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix. Radiat Oncol. 7:132012.
19	Kang S, Nam BH, Park JY, Seo SS, Ryu SY, Kim JW, Kim SC, Park SY and Nam JH: Risk assessment tool for distant recurrence after platinum-based concurrent chemoradiation in patients with locally advanced cervical cancer: A Korean gynecologic oncology group study. J Clin Oncol. 30:2369–2374. 2012. View Article : Google Scholar : PubMed/NCBI
20	Pieterse QD, Kenter GG, Maas CP, de Kroon CD, Creutzberg CL, Trimbos JB and Kuile MM: Self-reported sexual, bowel and bladder function in cervical cancer patients following different treatment modalities: Longitudinal prospective cohort study. Int J Gynecol Cancer. 23:1717–1725. 2013. View Article : Google Scholar : PubMed/NCBI
21	Jiao XB, Hu J and Zhu LR: The safety of ovarian preservation in early-stage adenocarcinoma compared with squamous cell carcinoma of uterine cervix: A systematic review and meta-analysis of observational studies. Int J Gynecol Cancer. 26:1510–1514. 2016. View Article : Google Scholar : PubMed/NCBI
22	Kim TH, Kim MH, Kim BJ, Park SI, Ryu SY and Cho CK: Prognostic importance of the site of recurrence in patients with metastatic recurrent cervical cancer. Int J Radiat Oncol Biol Phys. 98:1124–1131. 2017. View Article : Google Scholar : PubMed/NCBI
23	Bhatla N, Aoki D, Sharma DN and Sankaranarayanan R: Cancer of the cervix uteri. Int J Gynaecol Obstet. 143 (Suppl 2):S22–S36. 2018. View Article : Google Scholar : PubMed/NCBI
24	Salani R, Khanna N, Frimer M, Bristow RE and Chen LM: An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of gynecologic oncology (SGO) recommendations. Gynecol Oncol. 146:3–10. 2017. View Article : Google Scholar : PubMed/NCBI
25	Yilmaz B, Dağ S, Ergul N and Çermik TF: The efficacy of pretreatment and after treatment 18F-FDG PET/CT metabolic parameters in patients with locally advanced squamous cell cervical cancer. Nucl Med Commun. 40:219–227. 2019. View Article : Google Scholar : PubMed/NCBI
26	Liu J, Yuan S, Wang L, Sun X, Hu X, Meng X and Yu J: Diagnostic and predictive value of using RGD PET/CT in patients with cancer: A systematic review and meta-analysis. Biomed Res Int. 2019:85347612019.PubMed/NCBI
27	Kitajima K, Suzuki K, Nakamoto Y, Onishi Y, Sakamoto S, Senda M, Kita M and Sugimura K: Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence. Eur J Nucl Med Mol Imaging. 37:1490–1498. 2010. View Article : Google Scholar : PubMed/NCBI
28	Sironi S, Picchio M, Landoni C, Galimberti S, Signorelli M, Bettinardi V, Perego P, Mangioni C, Messa C and Fazio F: Post-therapy surveillance of patients with uterine cancers: Value of integrated FDG PET/CT in the detection of recurrence. Eur J Nucl Med Mol Imaging. 34:472–479. 2007. View Article : Google Scholar : PubMed/NCBI
29	Bentivegna E, Uzan C, Gouy S, Leboulleux S, Duvillard P, Lumbroso J, Haie-Meder C, Schlumberger M and Morice P: Correlation between [18f]fluorodeoxyglucose positron-emission tomography scan and histology of pelvic nodes in early-stage cervical cancer. Anticancer Res. 30:1029–1032. 2010.PubMed/NCBI
30	Chou HH, Chang TC, Yen TC, Ng KW, Hsueh S, Ma SY, Chang CJ, Huang HJ, Chao A, Wu TI, et al: Low value of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in primary staging of early-stage cervical cancer before radical hysterectomy. J Clin Oncol. 24:123–128. 2006. View Article : Google Scholar : PubMed/NCBI
31	Driscoll DO, Halpenny D, Johnston C, Sheehy N and Keogan M: 18F-FDG-PET/CT is of limited value in primary staging of early stage cervical cancer. Abdom Imaging. 40:127–133. 2015. View Article : Google Scholar : PubMed/NCBI
32	Maffione AM, Piva M, Tsamita CS, Nanni C, Castellucci P, Ambrosini V, Lopci E, Musto A, Rampin L, Grassetto G, et al: Positron-emission tomography in gynaecologic malignancies. Arch Gynecol Obstet. 280:521–528. 2009. View Article : Google Scholar : PubMed/NCBI
33	Chong A, Ha JM, Jeong SY, Song HC, Min JJ, Bom HS and Choi HS: Clinical usefulness of (18)F-FDG PET/CT in the detection of early recurrence in treated cervical cancer patients with unexplained elevation of serum tumor markers. Chonnam Med J. 49:20–26. 2013. View Article : Google Scholar : PubMed/NCBI
34	Pan L, Cheng J, Zhou M, Yao Z and Zhang Y: The SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) and serum squamous cell carcinoma antigen (SCC-ag) function as prognostic biomarkers in patients with primary cervical cancer. J Cancer Res Clin Oncol. 138:239–246. 2012. View Article : Google Scholar : PubMed/NCBI